Facing cross claims by Pitcher Partners in two shareholder class actions alleging the accounting firm wrongly signed off on Slater & Gordon’s financial reports ahead of a share price nosedive, the law firm and its ex-directors say they relied on the auditor to ensure the veracity of the statements.
Domino’s Pizza says it will defend a class action filed against it on behalf of thousands of delivery drivers and in-store workers who were allegedly systemically underpaid by franchisees over a five-year period.
Mortgage provider and Brisbane Broncos sponsor Firstmac has hit fintech giant Zip Co with a lawsuit for allegedly infringing its “Zip” trade mark.
Media companies facing defamation suits by a former youth centre detainee are liable for third-party comments posted on their Facebook pages, a judge has ruled in a groundbreaking decision.
The Western Australian parliament will this week introduce a new class actions regime modelled on the federal scheme, in a move the state Attorney-General says will enhance access to justice and improve efficiency.
Dairy supplier Murray Goulburn has agreed to pay $42 million to settle one of two shareholder class actions over a 2016 profit forecast revision that sent the co-op’s unit price falling more than 40 per cent in five days.Ā
A firm owned by solicitor Mark Elliot has launched an appeal challenging costs orders made against it in a stayed class action against winemaker Treasury Wine Estates.
Landowners above the Sydney Metro underground tunnel will be allowed to claim compensation before construction is complete, with a court also preparing to consider potential compensation for any reduced development potential.
Three shareholder class actions against RCR Tomlinson have been allowed to continued, setting up a class action beauty contest over who will lead the litigation against the failed engineering company.
Global pharmaceutical giant Pfizer has successfully defended the patent for its sedative drug Precedex against a validity challenge, a big win for the drug maker after a US court found last year that its patents for a ready-to-use version of the drug were invalid for obviousness.